Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.

EULAR calls for privacy, transparency when using big data in RMD research

Elvira Manzano
01 Aug 2019

Privacy and transparency are among the core points to consider when utilizing big data in rheumatic and musculoskeletal disorders (RMDs), according to the first EULAR-endorsed recommendations for use of big datasets in research.

The use and implementation of big data provide opportunities for better patient care and clinical decision-making, yet no academic societies have thus far developed guidelines to guide practice and ethics until the EULAR recommendations.

EULAR’s “points to consider” were drafted by a multidisciplinary task force of 14 international experts to synthesize essential issues surrounding big data acquisition, obtain a consensus, and provide a framework that will guide the collection, analysis, and use of such in RMDs. [Ann Rheum Dis 2019;doi:10.1136/annrheumdis-2019-215694]

The term big data may be widely used but there is not one commonly accepted definition, said the taskforce; hence the first overarching principle defines big data. “The term ‘big data’ itself has a broad definition and could define the large-scale datasets that include imaging data, electronic health records, or administrative claim records, among others,” said principal author Dr Laure Gossec of the Sorbonne University in Paris, France. “Big data is also used to refer to specific analytics and statistical methods, such as artificial intelligence and machine learning.”

Ethical issues related to privacy, confidentiality, and transparency when using big data should be considered, said the taskforce, even as it highlighted the unprecedented opportunities big data could provide  in terms of transformative discoveries to improve RMD research and practice.  The ultimate goal of utilizing big data in RMDs is to improve the health, lives, and care of patients, including health promotion, assessment, prevention, diagnosis, treatment and monitoring of disease, the taskforce added.

Some points to consider are the need for data harmonization, including the pooling of existing and future datasets to facilitate data interoperability; big data should be based on the FAIR (findable, accessible, interoperable, and reusable) principle; open data platforms should be preferred; privacy by design should be applied to the collection, processing, storage, analysis, and interpretation of big data which should be underpinned by interdisciplinary collaboration of scientists, relevant clinicians/healthcare professionals, and patients.

Other salient points include explicit reporting of the methods used to analyse big data in scientific publications; benchmarking of computational methods for big data used in RMD research; independent validation of conclusions and/or models drawn from big data prior to implementation; proactive implementation of findings in practice; and interdisciplinary training of clinicians and scientists on big data methods in RMDs.

“The use of big data … is a rapidly evolving field with the potential to profoundly modify RMD research and patient care,” said Gossec. “These first EULAR-endorsed points to consider address core issues including ethics, data sources and storage, data analyses, artificial intelligence, the need for benchmarking, adequate reporting of methods, interpretation, and implementation into clinical practice. We hope these points to consider will promote advances and homogeneity in the field of big data in RMDs and provide a useful guidance to other medical disciplines.” 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Pearl Toh, 6 days ago
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Elvira Manzano, 17 Nov 2020
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.